FDA Withdraws Pepaxto Approval After Low Survival Rate In Myeloma Patients
SILVER SPRING, Md. — The U.S. Food and Drug Administration has withdrawn its approval of Pepaxto-brand melphalan flufenamide, a drug approved in February 2021 under an accelerated approval process to treat...To view the full article, register now.
Already a subscriber? Click here to view full article